Class Action Signal

Class Action Signal

Class ActionsNews
Class ActionsNewsAboutContact
Public case informationLast updated

Aardvark Therapeutics Securities Class Action

Aardvark Therapeutics · ARD-101 drug candidate and related clinical trials · Ongoing Litigation

About this case

A pending federal securities class action alleges that Aardvark Therapeutics and certain officers and directors made materially false or misleading statements, or omitted material information, about the safety and development prospects of ARD-101 in offering documents and during the alleged class period. The case was filed in the U.S. District Court for the Southern District of California and remains ongoing.

Case overview

Defendant company
Aardvark Therapeutics
Product or service
ARD-101 drug candidate and related clinical trials
Case name
Aardvark Therapeutics Securities Fraud Class Action
Court case number
26-cv-04643
Case status
Ongoing Litigation
Lawsuit type
Securities
Reported harm
Misrepresentation

Important dates

Lead-plaintiff application
Aardvark Therapeutics lead plaintiff application

Participation information

Lead-plaintiff application

Investors who purchased Aardvark common stock pursuant or traceable to the February 2025 initial public offering, or acquired Aardvark securities between February 13, 2025, and May 14, 2026, may seek appointment as lead plaintiff, subject to court determination.

Ask the court for appointment as lead plaintiff by October 13, 2026. Investors should review the court filings and consult qualified legal counsel regarding their circumstances.

Type
Lead Plaintiff
Status
Open
Reported proof requirement
Unclear
Apply as lead plaintiff

Aardvark Therapeutics lead plaintiff application

Investors within the stated purchase periods may seek appointment as lead plaintiff in the securities class action.

A motion to serve as lead plaintiff must be filed with the court no later than October 13, 2026. The article states that serving as lead plaintiff is not required to share in any potential future recovery.

Type
Lead Plaintiff
Status
Open
Reported proof requirement
Unclear
Apply as lead plaintiff

Settlement Claim

The action concerns persons and entities, other than the defendants, who purchased or otherwise acquired Aardvark common stock pursuant or traceable to the February 13, 2025 IPO offering documents and/or Aardvark securities between February 13, 2025 and May 14, 2026, inclusive, and who may have suffered losses.

Type
Settlement Claim

Discuss the Action With Pomerantz LLP

Contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, extension 7980, to discuss the action.

Type
Law Firm Signup

Aardvark Therapeutics shareholder consultation

The firm invites people who purchased Aardvark shares between February 13, 2025 and May 14, 2026 and experienced an investment loss to discuss their legal rights.

Contact Corey D. Holzer, Esq. by email or telephone, or use the law firm's case webpage for more information.

Type
Law Firm Signup

Robbins LLP Investor Inquiry

Investors who purchased or otherwise acquired Aardvark Therapeutics securities during the stated offering or class period and suffered losses may contact Robbins LLP for information about the lawsuit and becoming lead plaintiff.

Contact Robbins LLP by submitting an inquiry, emailing attorney Aaron Dumas, Jr., or calling (800) 350-6003.

Type
Law Firm Signup
Reported proof requirement
Unclear
Source version Original press release

Sources